Maryland Department of Health (MDH) Center for Cancer Prevention and Control Cigarette Restitution Fund Cancer

Prevention, Education, Screening and Treatment (CRF CPEST) Program Minimal Clinical Elements for Lung Cancer Detection and Diagnosis Updated April 2024

Goal: The goal of the Minimal Clinical Elements for Lung Cancer Screening and Diagnosis is to provide evidence-based lung cancer screening and diagnostic guidelines for Maryland Cigarette Restitution Fund Cancer Prevention, Education, Screening and Treatment Program providers.

Sections	Page
I. Client Eligibility Criteria	2
II. Prerequisite to Receiving an Annual Low-Dose Computed Tomography (LDCT) Lung Cancer Screening	3
III. Reporting	4
IV. Management of Results	4
V. Additional Procedures and Program Coverage	5
VI. References	6
VII. Helpful Links	6
VIII. Lung Cancer Medical Advisory Committee Members	7

Section I: Client Eligibility Criteria

A. Screening

An individual that meets both criteria listed below will be enrolled in the CRF CPEST Program's Lung Cancer Screening Module for screening, diagnostic testing, and, if funds are available, treatment services.

- 1. An individual who is at High Risk for lung cancer:
 - o Anyone, age 50 to 80 years, AND;
 - ≥20 pack-year smoking history.
- 2. An individual who meets the residency, income, and health insurance requirements listed below:
 - o Is a Maryland resident; AND
 - Has an annual household income < 250% of the federal poverty level; AND
 - Has no health insurance OR has health insurance that does not completely pay for required services OR has health insurance but will need assistance or navigation services to obtain screening, diagnostic and, if applicable, treatment services.

Note:

- Screening should be discontinued once a person develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery; however, those who are no longer eligible for curative lung surgery but are eligible for radiotherapy may continue annual lung cancer screening.
- If a person is program eligible <u>and</u> has a prior history of lung cancer, annual lung cancer screening with LDCT may resume 5 years after diagnosis of lung cancer at the discretion of the provider and client (refer to 'Special Situations' on page 5).

B. Diagnostic Referral

An individual who was <u>screened outside of the CRF CPEST program</u> but requires CRF CPEST-funded diagnostic services and meets the three criteria listed below will be enrolled in the CRF CPEST Program's Lung Cancer Diagnostic and Treatment Module for diagnostic testing and, if funds are available, treatment services.

- 2. Anyone, age 50 to 80 years, AND;
- 3. Provides the local CRF CPEST Program with documentation of abnormal finding(s) from a <u>lung cancer screening LDCT</u> and recommended diagnostic work up to rule out lung cancer, AND;
- 4. Meets the residency, income, and health insurance requirements as listed below:
 - Is a Maryland resident; AND
 - \circ Has an annual household income $\leq 250\%$ of the federal poverty level; AND
 - Has no health insurance OR has health insurance that does not completely pay for required services OF has health insurance but will need assistance or navigation services to obtain screening, diagnostic testing and, if applicable, treatment services.

Section II: Prerequisite to Receiving an Annual LDCT Lung Cancer Screening

A client enrolled in the CRF CPEST Lung Cancer Screening Module for screening must receive the following services before receiving an annual LDCT lung cancer screening:

- 1. If a former smoker, the client must receive counseling on the importance of maintaining cigarette smoking abstinence. If currently smoking, the client must have counseling about the importance of smoking cessation and be furnished with information about tobacco cessation interventions.
- 2. A written order for LDCT lung cancer screening must be appropriately documented in the client's medical records and must meet the following criteria:
 - For <u>initial</u> LDCT lung cancer screening services, the client must receive a written order for a LDCT lung cancer screening furnished by a physician or qualified non-physician practitioner (meaning a physician assistant or nurse practitioner) during a lung cancer screening counseling and shared decision making visit. A lung cancer screening counseling and shared decision making visit includes the following elements:
 - a) Determination of the client's eligibility including age, absence of signs or symptoms of lung cancer, calculation of cigarette smoking pack-years (Number of packs of cigarettes smoked per day x Number of years smoked = Pack years)
 - b) Construction of a shared decision with the client, including the use of one or more decision aids, to include benefits and harms of screening, follow-up diagnostic testing, over-diagnosis, false positive rate, and total radiation exposure;
 - c) Counseling on the importance of adherence to annual lung cancer LDCT screening, impact of comorbidities and ability or willingness to undergo diagnosis and treatment;
 - d) Counseling on the importance of maintaining cigarette smoking abstinence if former smoker; or the importance of smoking cessation and furnishing of information about tobacco cessation interventions if current smoker; and
 - e) A written order for lung cancer screening with LDCT.
 - For <u>subsequent LDCT</u> lung cancer screenings, the client must receive a written order for LDCT lung cancer screening, which may be furnished during any appropriate visit with a physician or qualified non-physician practitioner. If a physician or qualified non-physician practitioner elects to provide a lung cancer screening counseling and shared decision making visit for subsequent lung cancer screenings with LDCT, the visit must meet the criteria similar to an initial LDCT counseling and shared decision making visit.
 - Written orders for both initial and subsequent LDCT lung cancer screenings must contain the following information, which must be appropriately documented in the client's medical records:
 - a) Client's date of birth;
 - b) Number of pack-year smoking history;
 - c) Current smoking status
 - d) Statement that the client is asymptomatic for lung cancer, though they may have signs or symptoms of other diseases (chronic obstructive pulmonary disease [emphysema and chronic bronchitis)] and pulmonary fibrosis);
 - e) Statement verifying if the client has been furnished with a counseling and shared decision making discussion;
 - f) National Provider Identifier (NPI) of the ordering practitioner.

Section III: Reporting

Computed Tomography (CT) findings should be reported using the most current Lung CT Screening Reporting & Data System (Lung-RADS®), located at https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads

For reporting of CT findings, please use the ACR–STR Practice Parameter for the Performance and Reporting of Lung Cancer Screening Thoracic Computed Tomography (CT), available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-LungCaScr.pdf?la=en

Section IV: Management of Results

Please refer to the most current National Comprehensive Cancer Network (NCCN) Lung Cancer Screening Guidelines for the management of nodules on the initial, follow-up, or annual LDCT, located at https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1441

To access the NCCN Lung Cancer Screening and Diagnosis guidelines, program providers and staff will need to create an account at https://www.nccn.org/. It is free to create an account. After an account is created, log in to your account using your ID and password, and follow these steps to access the NCCN Lung Cancer Screening and Diagnosis guidelines:

- Click on the "Guidelines" link in the top header.
- Then click on the "Detection, Prevention, and Risk Reduction" link.
- Finally, click on the "Lung Cancer Screening" link.

Note:

- For Lung-RADS category 3 results, the ordering provider may refer the client to the appropriate specialist (e.g. Pulmonologist or Thoracic Surgeon) for evaluation and/or possible presentation to the multidisciplinary team.
- For significant findings unrelated to lung cancer (e.g. suspicious for other cancers, chronic obstructive pulmonary disease, moderate to severe coronary artery calcification or an aortic aneurysm):
 - o **If the client has a Primary Care Provider (PCP)**: the local CRF CPEST program will forward copies of reports and refer the client to his/her PCP for follow-up of finding(s).
 - o **If the client does not have a PCP**: the local CRF CPEST program will link the client to a PCP and forward copies of the reports for the management of findings and determination of appropriate follow-up of findings other than lung cancer.

Section V: Additional Procedures and Program Coverage

Providers should consult with the local CRF CPEST Program for questions about coverage for payment of procedures. Reimbursement is based on client eligibility and availability of local CRF CPEST Program funds.

Special Situations: If an individual is program eligible <u>and</u> has a prior history of lung cancer, annual lung cancer screening with LDCT may resume 5 years after diagnosis of lung cancer at the discretion of the provider and client. Enrollment into the Lung Cancer Screening Module is on a case-by-case basis. Prior to enrollment, local CRF CPEST programs must first contact the MDH Nurse Consultant for guidance.

Reimbursement for Additional Screening or Diagnostic Procedures: Only procedures recommended in the most current NCCN guidelines, based on imaging or histologic findings, will be CRF CPEST-funded. Additional or alternative procedures are usually not paid for by the CRF CPEST Program. Please contact your local CRF CPEST Program for more information.

Reimbursement for Treatment Procedures: Please contact your local CRF CPEST Program for more information about the coverage of these procedures:

- Surgical or oncology consult visits
- Follow-up surgical or oncology visits
- Chemotherapy
- Radiation Therapy
- Surgery
- Complications related to a CRF CPEST funded diagnostic procedure or treatment
- Palliative care

Section VI: References

American College of Radiology. ACR–STR Practice Parameter For The Performance And Reporting Of Lung Cancer Screening Thoracic Computed Tomography (CT). https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-LungCaScr.pdf. Accessed March 21, 2024

American College of Radiology. Lung CT Screening Reporting & Data System (Lung-RADS®). Available at https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads. Accessed March 21, 2024

National Cancer Institute (NCI). Pack Year. Available at https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pack-year. Accessed March 21, 2024

National Comprehensive Cancer Network. NCCN Guidelines Detection, Prevention, and Risk Reduction. Available at https://www.nccn.org/guidelines/category 2. Accessed March 21, 2024

US Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(10):962–970. doi:10.1001/jama.2021.1117 Available at https://jamanetwork.com/journals/jama/fullarticle/2777244. Accessed March 21, 2024

Wolf AMD, Oeffinger KC, Shih TY, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024; 74(1): 50-81. doi:10.3322/caac.21811. Available at https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21811. Accessed March 21, 2024

Section VII: Helpful Links

National Lung Cancer Roundtable Resource Center

This website includes resources for patients, and education and training materials for healthcare teams.

Available at: https://nlcrt.org/resource-center/

American College of Radiology Lung Cancer Screening Resources

This website includes resources on screening guidelines, billing information, and status of screening coverage.

Available at: https://www.acr.org/Clinical-Resources/Lung-Cancer-Screening-Resources

Section VIII: Medical Advisory Committee (MAC) Lung Cancer Subcommittee

The following members participated in the formulation of the Minimal Clinical Elements:

Kathy J. Helzlsouer, MD, MHS

MAC Chairperson

Medical Oncologist and Epidemiologist Adjunct Professor, Johns Hopkins Bloomberg School of Public Health

Arun Bhandari, MD

Hematologist/Oncologist Chesapeake Oncology Hematology Associates

Stephen M. Cattaneo, MD, MBA

Medical Director of Thoracic Oncology, Luminis Health Assistant Professor of Thoracic Surgery, Johns Hopkins Medical Institutions

Elliot K. Fishman, MD

Professor of Diagnostic Radiology of Oncology Surgery, Johns Hopkins Hospital

Charles White, MD

Director of Thoracic Imaging and Vice-Chairman for Clinical Affairs, University of Maryland Medical Center

Rex Chin-Wei Yung, MD

Pulmonologist/Critical Care Physician

Center for Cancer Prevention and Control, Maryland Department of Health Staff

Sadie Peters, MA, MD, MHS, Medical Director, Center for Cancer Prevention and Control Ken Lin Tai, MD, MPH, Director, Center for Cancer Prevention and Control Cristina Ruiz-McCalla, BS, Direct Services Lead, Cancer Screening Programs Unit JoAnn Johnston, BSN, RN, Program Nurse Consultant, Cancer Screening Programs Unit Srishti Singh, MSN/Ed, RN, Program Nurse Consultant, Cancer Screening Programs Unit